New Chief Medical Officer for Cardio3 Biosciences

Warren Sherman has more than three decades of experience in the cardiovascular and cell therapy fields

Dr Warren Sherman takes over as Chief Medical officer at Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and reconstructive therapies, on 1 November.

In this new role, Sherman will leverage his expertise in the cardiovascular and cell therapy fields to support the development of the Belgian company's pipeline, both in cell therapies and cardiovascular diseases.

Sherman has more than 30 years’ experience in the field of cardiology, with a focus on cell-based therapies for post myocardial infarction and heart failure.

Before joining Cardio3 BioSciences, Sherman was at the Columbia University Medical Centre in New York, where he served in a number of capacities.

Sherman founded the Cardiovascular Research Foundation’s International Conference on Cell Therapy for Cardiovascular Disease (IC3D). Started in 2004, this annual conference gathers leaders from the international community who present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Research & Development

Cardio3 BioSciences to open manufacturing site in Rochester, MN, US

To support CHART-2 Phase III trial and growth in the US
Research & Development

Cardio3 BioSciences establishes US subsidiary

Belgian biotechnology firm adds Rochester, MN operation
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Subscribe now